Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2023-04-12 | John F. McDonald 62 Yes AC: M Compensation: $391,077 |
| 2024-03-27 | John F. McDonald has served as a director of Geron since September 2022. Since October 2018, Mr. McDonald has served as Corporate Vice President, Global Head of Business Development and Mergers and Acquisitions, for Novo Nordisk A/S, a global pharmaceutical company, where he leads business development and merger and acquisition activities, investment strategies and participates in the creation of research, early development, and therapeutic pipeline diversification and augmentation strategies. The Board believes Mr. McDonald’s extensive experience in business development related to pharmaceutical products, as well as his deep understanding of creating strategic relationships in the pharmaceutical industry, qualifies Mr. McDonald to BE ELECTED as a director. For the year ended December 31, 2023, Mr. McDonald received $55,000 in cash fees and $293,400 in stock option awards, totaling $348,400. |
| 2025-04-08 | John F. McDonald has served as a director of Geron since September 2022. ... The current members of the Audit Committee are Ms. O’Farrell, Dr. Lawlis and Mr. McDonald. ... The current members of the Compensation Committee are Dr. Aggarwal, Dr. Spiegel, and Dr. Molineaux. ... Dr. Aggarwal, Ms. O’Farrell and Mr. McDonald are the current members of the Strategic Committee and served on the Strategic Committee for the year ended December 31, 2024. |
Data sourced from SEC filings. Last updated: 2026-02-03